Purefarma and Pura Vida vape cartridge products set to expand footprint across Canada

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”) today announced that its vape products are available for purchase in British Columbia through authorized Liquor Distribution Branch (“LDB”) channels and in select licensed cannabis retail locations in Manitoba. In BC, all seven vape cartridge products offered by Heritage including Pura Vida CBD 4:1 Honey Oil, and Indica, Sativa and Hybrid Honey Oil vape cartridges, as well as Purefarma Moon, Sun and Earth vape cartridges will be available to consumers, while in Manitoba, Purefarma CBD Earth, and Pura Vida’s Indica, Sativa, and Hybrid Honey Oil vape cartridges will be available for purchase.


Heritage CEO Clint Sharples said, “We are thrilled to have our vape cartridges on the shelves in Manitoba and British Columbia. Purefarma Indica and Sativa have already sold out in BC — a clear indication of the strong demand for our full spectrum products, which contain no potentially harmful additives or back added terpenes. Heritage is delivering products with the highest quality standards while remaining affordably priced.”

“I am extremely excited for the release of products from Heritage,” said Elaine Nuessler, Purple Hemp Co.’s Owner and Cannabis Consultant. “I have worked alongside Purefarma’s grassroots team for over six years assisting our clients with their medical cannabis journey. The integrity, compassion, and expertise of Heritage has created some of the highest quality and most effective products in Canada. I know many of our clients would attest to that.”

About Heritage Cannabis Holdings Corp.

Heritage Cannabis Holdings Corp. is a vertically integrated cannabis company that owns two Health Canada approved licenced producers, Voyage Cannabis Corp. and CannaCure Corp., both of which also have industrial hemp licenses. Working under its licenses, Heritage has two additional subsidiaries, Purefarma Solutions, that provide extraction services, and a Medical Services Division which is focused on cannabis based medical solutions. As the parent company, Heritage provides the synergies and resources for its subsidiaries to advance their medical and adult use products and services both domestically and internationally.

Corey Herscu for Heritage Cannabis
corey@verbfactory.com
416-300-3030

or

Kelly Castledine
Heritage Cannabis Holdings Corp.
Tel: 647-660-2560
kcastledine@heritagecann.com

News Provided by Business Wire via QuoteMedia

– Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020 inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

Keep reading... Show less

Receipt of licence will be a major milestone in the Company’s commercialization and white-label plans

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“ BevCanna ” or the “ Company ”) is pleased to announce that it has moved to the Final Review Stage for a Standard Processing Licence from Health Canada.

Keep reading... Show less

 Nutritional High International Inc. (CSE: EAT) (OTC Pink: SPLIF) (“Nutritional High” or the “Company”) is pleased to announce that the Company has completed the proposed conversion of the 10% senior unsecured convertible Debentures (the “10% Debentures”) described in the management information circular dated September 17, 2020.

In accordance with the amendment approved at the meeting of the Debentureholders held on October 8, 2020, approved by the Canadian Securities Exchange, the Company has completed the forced conversion of the 10% Debentures at $.02 per share.

Keep reading... Show less

 Nutritional High International Inc.(CSE: EAT) (OTC Pink: SPLIF) (“Nutritional High” or the “Company”) announces today that it has made an application to the Ontario Securities Commission to approve a temporary management cease trade order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”), which, if granted, will prohibit trading in securities of the Company by its Chief Executive Officer, Chief Financial Officer and certain other insiders of the Company, whether direct or indirect, so long as the 2020 Filings (as defined below) remain outstanding. The issuance of an MCTO would generally not affect the ability of persons who are not, or who have not been, directors, officers or other insiders of the Company to trade in the Company’s securities.

In discussion with its auditors, the Company has determined that it is not able to meet the November 30, 2020 filing deadline (the “Filing Deadline“) for its audited financial statements for the year ended July 31, 2020, the management’s discussion and analysis and the related CEO and CFO certification relating to the 2020 financial statements (collectively, the “2020 Filings“). Although the audit process is progressing, the auditors anticipate some delays in completing the audit process, such that the Company is not able to meet the Filing Deadline for the 2020 Filings.

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) announced today that the Company has entered into a convertible debenture extension and amendment agreement (the “Amending Agreement”) dated October 29, 2020 with Quinsam Capital Corporation (the “Lender”). The Amending Agreement amends certain terms of the 10% convertible debenture dated November 1, 2017 in the principal amount of $262,500 and the 10% convertible debenture dated December 10, 2017 in the principal amount of $237,500, in each case, issued by the Company in favour of the Lender (collectively, the “Convertible Debentures”).

Under the terms of the Amending Agreement, the Lender has agreed to extend the maturity dates of the Convertible Debentures from November 1, 2020 and December 10, 2020, respectively, until April 30, 2021 (the “Amended Maturity Date“). The Amending Agreement also provides that interest on the principal amount outstanding under the Convertible Debentures will be payable by the Company at the originally stated interest rate of 10% per annum until their respective original maturity dates and, thereafter, at the amended interest rate of 12% per annum until the Amended Maturity Date. In addition, the conversion terms of the Convertible Debentures were amended to provide that the outstanding principal owing under the Convertible Debentures may be converted into common shares of the Company at a price of $0.125 per common share instead of $0.15 per common share. All other terms and conditions of the Convertible Debentures remain unchanged. In consideration for the amendments under the Amending Agreement, the Company agreed to pay to the Lender an extension fee of $20,000.

Keep reading... Show less